Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Personalized Medicine

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 1884823

Cover Image

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 1884823

Companion Diagnostics

PUBLISHED:
PAGES: 482 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Companion Diagnostics Market to Reach US$14.1 Billion by 2030

The global market for Companion Diagnostics estimated at US$7.3 Billion in the year 2024, is expected to reach US$14.1 Billion by 2030, growing at a CAGR of 11.6% over the analysis period 2024-2030. Assay Kits & Reagents, one of the segments analyzed in the report, is expected to record a 10.9% CAGR and reach US$9.1 Billion by the end of the analysis period. Growth in the Software & Services segment is estimated at 13.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 15.6% CAGR

The Companion Diagnostics market in the U.S. is estimated at US$2.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.9 Billion by the year 2030 trailing a CAGR of 15.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.5% and 10.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.2% CAGR.

Companion Diagnostics - Key Trends and Drivers

Companion diagnostics are an integral component of precision medicine, designed to identify the suitability of specific treatments for individual patients based on their unique genetic makeup or other biomarkers. These diagnostic tests are critical in the field of oncology, where they help determine the most effective therapies for cancer patients, ensuring treatments are tailored to the molecular profile of a patient's tumor. By enabling personalized treatment plans, companion diagnostics improve the efficacy and safety of therapies, reduce adverse effects, and ultimately enhance patient outcomes. They work by identifying patients who are most likely to benefit from a particular therapeutic product, ensuring that the right drug is administered to the right patient at the right time. This approach is transforming the landscape of medical treatment, moving away from the one-size-fits-all model to more targeted and individualized care.

The technological advancements in molecular diagnostics and genomics are significantly driving the evolution of companion diagnostics. Next-generation sequencing (NGS) and polymerase chain reaction (PCR) are among the key technologies that have enhanced the precision and speed of companion diagnostics. These technologies enable comprehensive genomic profiling and accurate detection of genetic mutations and alterations associated with various diseases, particularly cancer. Additionally, the integration of artificial intelligence (AI) and machine learning in data analysis has further refined the accuracy of these diagnostics, allowing for more precise and reliable results. The development of multiplex assays, which can detect multiple biomarkers simultaneously, has also expanded the scope and efficiency of companion diagnostics. This technological progress is not only improving diagnostic capabilities but also fostering collaborations between pharmaceutical companies and diagnostic manufacturers to co-develop drugs and companion tests, thereby accelerating the delivery of personalized therapies to patients.

The growth in the companion diagnostics market is driven by several factors. The increasing prevalence of cancer and other chronic diseases necessitates the development of targeted therapies, which in turn boosts the demand for companion diagnostics. Regulatory agencies, such as the FDA, are emphasizing the importance of companion diagnostics in the drug approval process, encouraging pharmaceutical companies to incorporate these tests into their clinical development strategies. The rise of precision medicine and the growing adoption of personalized treatment approaches are also propelling market growth. Furthermore, advancements in molecular diagnostics technologies, such as NGS and digital PCR, are enhancing the accuracy and efficiency of companion diagnostics, making them more accessible and reliable. The expansion of biomarker discovery and the increasing use of biomarkers in drug development are generating new opportunities for the market. Additionally, the collaboration between diagnostic companies and pharmaceutical firms is fostering innovation and accelerating the development of new companion diagnostics. These factors collectively contribute to the robust growth and widespread adoption of companion diagnostics, transforming the landscape of personalized medicine and improving patient care.

SCOPE OF STUDY:

The report analyzes the Companion Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Assay Kits & Reagents, Software & Services); Technology (Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology, Other Technologies); Indication (Oncology Indication, Neurology Indication, Other Indications); End-Use (Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 47 Featured) -

  • Abbott Molecular
  • Agilent Technologies, Inc.
  • bioMerieux SA
  • Cepheid
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Foundation Medicine Inc.
  • Laboratory Corporation of America(R) Holdings
  • Leica Biosystems Nussloch GmbH
  • Merck & Co. Inc.
  • Myriad Genetics Inc.
  • NeoGenomics Laboratories, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Inc.
  • Thermo Fischer Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP-6736

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • Companion Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Technological Advancements in Molecular Diagnostics Propel Growth in the Companion Diagnostics Market
    • Integration of Next-Generation Sequencing (NGS) and PCR Expands Addressable Market Opportunity
    • Rising Adoption of Precision Medicine Throws the Spotlight on Personalized Treatment Approaches
    • Development of Multiplex Assays Drives Efficiency and Market Expansion
    • AI and Machine Learning in Data Analysis Strengthen Business Case for Companion Diagnostics
    • Increasing Prevalence of Cancer and Chronic Diseases Generates Demand for Targeted Therapies
    • Regulatory Emphasis on Companion Diagnostics in Drug Approval Processes Propels Market Growth
    • Expansion of Biomarker Discovery Accelerates Demand for Companion Diagnostics
    • Growing Use of Biomarkers in Drug Development Enhances Market Opportunities
    • Rising Investment in Genomic Research Drives Adoption of Companion Diagnostics
    • Digital Transformation in Healthcare Sustains Growth in the Companion Diagnostics Market
    • Personalized Treatment Strategies Promise Improved Patient Outcomes
    • Increasing Accessibility and Affordability of Advanced Diagnostic Technologies Generate Market Growth
    • Evolution of Healthcare Policies and Reimbursement Frameworks Propel Adoption of Companion Diagnostics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Companion Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Companion Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Assay Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Assay Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Assay Kits & Reagents by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction (PCR) Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Polymerase Chain Reaction (PCR) Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Polymerase Chain Reaction (PCR) Technology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immunohistochemistry (IHC) Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Immunohistochemistry (IHC) Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Immunohistochemistry (IHC) Technology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for In Situ Hybridization (ISH) Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for In Situ Hybridization (ISH) Technology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Next-Generation Sequencing (NGS) Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Next-Generation Sequencing (NGS) Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Next-Generation Sequencing (NGS) Technology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Oncology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Oncology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Oncology Indication by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Neurology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Neurology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Neurology Indication by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Pharma & Biopharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Pharma & Biopharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Pharma & Biopharma Companies End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Reference Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Reference Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Reference Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for CROs End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Companion Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 110: France Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: France 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Germany 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Italy 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Italy 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 146: UK Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: UK 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: UK 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Spain 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Spain 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Spain 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 167: Spain Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Spain Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Spain 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Russia 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Russia 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Russia 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 179: Russia Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Russia Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Russia 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Europe 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Companion Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Asia-Pacific 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Australia 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Australia 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Australia 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 218: Australia Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Australia Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Australia 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 221: India Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: India 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 224: India Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: India 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 227: India Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: India 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 230: India Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: India Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: India 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: South Korea 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: South Korea 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: South Korea 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: South Korea Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: South Korea 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Companion Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Revenues for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Latin America 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Latin America 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Latin America 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Latin America 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Argentina 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Argentina 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Argentina 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Argentina Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Argentina 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Brazil 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Brazil 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Brazil 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Brazil Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Brazil 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Mexico 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Mexico 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Mexico 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Mexico Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Mexico 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Rest of Latin America 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Companion Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Revenues for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Middle East 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Middle East 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Middle East 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Middle East 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Iran 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Iran 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Iran 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 344: Iran Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Iran Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Iran 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Israel 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Israel 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Israel 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 356: Israel Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Israel Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Israel 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: Saudi Arabia 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: UAE 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: UAE 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: UAE 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 380: UAE Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: UAE Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: UAE 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: Rest of Middle East 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Companion Diagnostics by Offering - Assay Kits & Reagents and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Africa 15-Year Perspective for Companion Diagnostics by Offering - Percentage Breakdown of Value Revenues for Assay Kits & Reagents and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: Africa 15-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Revenues for Polymerase Chain Reaction (PCR) Technology, Immunohistochemistry (IHC) Technology, In Situ Hybridization (ISH) Technology, Next-Generation Sequencing (NGS) Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for Companion Diagnostics by Indication - Oncology Indication, Neurology Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 403: Africa 15-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Revenues for Oncology Indication, Neurology Indication and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 404: Africa Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Africa Historic Review for Companion Diagnostics by End-Use - Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 406: Africa 15-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies End-Use, Reference Laboratories End-Use, CROs End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!